Coya Therapeutics' COYA 303 Shows Promising Immunomodulatory Effects in Preclinical Study — Coya Therapeutics, Inc.

Event summary

Coya Therapeutics published preclinical results for COYA 303 in the International Journal of Molecular Sciences on September 8, 2026.
COYA 303, a combination of low-dose IL-2 and a GLP-1 receptor agonist, demonstrated significant immunomodulatory effects in a subacute low-dose LPS mouse model.
The study showed reductions in pro-inflammatory markers and increases in anti-inflammatory markers both peripherally and in cortical and hippocampal tissues.
The combination treatment was initiated 24 hours after inflammatory induction, showing efficacy even after inflammation had begun.

The big picture

Coya Therapeutics' preclinical study results for COYA 303 highlight the growing interest in combination therapies for neurodegenerative diseases. The study's findings suggest that targeting both pro-inflammatory myeloid cells and regulatory T cells could offer a more comprehensive approach to managing inflammation-driven neurodegenerative conditions. This aligns with broader industry trends towards multi-targeted therapies for complex diseases.

What we're watching

Clinical Translation: Whether the preclinical efficacy of COYA 303 will translate into clinical settings for neurodegenerative diseases.
Combination Therapy: The pace at which combination therapies like COYA 303 will gain traction in treating complex neurodegenerative conditions.
Regulatory Pathway: How Coya Therapeutics will navigate the regulatory pathway for COYA 303, given the novel combination approach.